The treatment of Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) patients who harbor the T315I BCR-ABL1 mutation or who have two or more mutations in the same BCR-ABL1 molecule is particularly challenging since first and second-generation Tyrosine Kinase Inhibitors (TKIs) are ineffective. Ponatinib, blinatumomab, chemotherapy and transplant are the currently available options in these cases.

The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report

De Benedittis, Caterina;Papayannidis, Cristina;Venturi, Claudia;Abbenante, Maria Chiara;Paolini, Stefania;Parisi, Sarah;Sartor, Chiara;Cavo, Michele;Martinelli, Giovanni;Soverini, Simona
2017

Abstract

The treatment of Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) patients who harbor the T315I BCR-ABL1 mutation or who have two or more mutations in the same BCR-ABL1 molecule is particularly challenging since first and second-generation Tyrosine Kinase Inhibitors (TKIs) are ineffective. Ponatinib, blinatumomab, chemotherapy and transplant are the currently available options in these cases.
BMC CANCER
De Benedittis, Caterina; Papayannidis, Cristina; Venturi, Claudia; Maria Chiara, Abbenante; Paolini, Stefania; Parisi, Sarah; Sartor, Chiara; Cavo, Michele; Martinelli, Giovanni; Soverini, Simona
File in questo prodotto:
File Dimensione Formato  
12885_2017_Article_3511.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 688.99 kB
Formato Adobe PDF
688.99 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11585/614566
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact